{
    "nct_id": "NCT00012857",
    "title": "Pain Management and Behavioral Outcomes in Patients With Dementia",
    "status": "COMPLETED",
    "last_update_time": "2015-04-06",
    "description_brief": "Dementia illness often co-exists with painful medical conditions associated with aging (e.g., degenerative joint disease, osteoarthritis, skin ulcers, back pain, headaches, cancer, or angina). While the standard practice is pain assessment for all patients, the elderly with dementia have special needs for assessment, management, and evaluation. When they are unable to verbalize pain, objective measurement of their discomfort are possible manifestations of pain. No research relates systemic pain treatment with reduction of negative problematic behaviors in patient dementia.",
    "description_detailed": "Background:\n\nDementia illness often co-exists with painful medical conditions associated with aging (e.g., degenerative joint disease, osteoarthritis, skin ulcers, back pain, headaches, cancer, or angina). While the standard practice is pain assessment for all patients, the elderly with dementia have special needs for assessment, management, and evaluation. When they are unable to verbalize pain, objective measurement of their discomfort are possible manifestations of pain. No research relates systemic pain treatment with reduction of negative problematic behaviors in patient dementia.\n\nObjectives:\n\nThe objectives of this research are (1) to elucidate the relationships between pain, discomfort, and agitation; and (2) to determine the influence that pain management has on decreasing the outcomes of discomfort, agitation, and confusion in nursing home residents.\n\nMethods:\n\nThis study used a randomized, double-blind, placebo-controlled, cross-over design. Each treatment arm lasted two weeks. The crossover point occurred without washout. One arm was acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN. Sites involved in the study included the Jewish Home for the Aged in San Francisco; Golden Gate Healthcare Center in San Francisco; Palo Alto VA Health Care System; Nursing Home Care Unit at Livermore. Patients were included who: are \\> 55 years; have severe dementia; have a documented painful condition not requiring opiates or a current medication regimen; unable to report pain consistently or reliably; be present and accept treatment for study duration; have \\> 1 episode of agitation per day. Patients with schizophrenia or severe Parkinson\ufffds are excluded. A research assistant (blind to treatment arm) tested each patient for discomfort, agitation, and confusion at baseline and two times per day on two days of the week for four weeks. Nurses rated patients for agitation each shift. Instruments included the Cohen-Mansfield Agitation Inventory, the Discomfort Scale, and the Confusion Assessment Method. Repeated measures analyses examined effect of treatment on the three behaviors (agitation, confusion, and discomfort).\n\nStatus:\n\nThe study is complete. Final report was submitted to HSR\\&D in August 2001.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "neuropsychiatric symptom improvement",
    "drug": [
        "acetaminophen 650 mg qid (active arm)"
    ],
    "placebo": [
        "placebo qid"
    ],
    "explanation_target": [
        "Reason: The trial description and title state the intervention is systemic pain treatment intended to decrease negative/problematic behaviors (agitation, mood, confusion) in patients with dementia \u2014 i.e., the goal is to improve neuropsychiatric/behavioral symptoms rather than to modify Alzheimer pathology or directly enhance cognition.",
        "Act (trial details extracted): The registered trial (NCT00012857) tests acetaminophen 650 mg four times daily versus placebo in a randomized, double-blind, placebo-controlled, crossover design (each arm two weeks). This identifies the drug as acetaminophen (a small-molecule analgesic) used here to target behavioral outcomes by treating pain. \ue200cite\ue202turn0search0\ue202turn0search2\ue201",
        "Reflect (classification justification): Although acetaminophen is a small-molecule analgesic, in this trial it is being used to treat pain with the stated intention of reducing agitation and other problematic/neuropsychiatric behaviors in dementia \u2014 matching the definition 'interventions alleviating behavioral or psychiatric symptoms.' Clinical evidence supports that pain treatment can reduce agitation and mood symptoms in dementia, consistent with classifying this trial as neuropsychiatric symptom improvement. \ue200cite\ue202turn0search5\ue202turn0search6\ue202turn0search4\ue201",
        "Web search results / sources used: (1) Trial registry entry showing intervention details (acetaminophen 650 mg qid vs placebo; NCT00012857). \ue200cite\ue202turn0search0\ue202turn0search2\ue201 (2) Cluster randomized trial and other RCT evidence that individualized pain treatment reduces agitation in dementia. \ue200cite\ue202turn0search5\ue202turn0search6\ue201 (3) Recent systematic review/meta-analysis showing association between pain and behavioral and psychological symptoms of dementia (BPSD), supporting the rationale for treating pain to improve neuropsychiatric outcomes. \ue200cite\ue202turn0search4\ue201",
        "Ambiguity/notes: The drug is a symptomatic analgesic (acetaminophen) rather than a disease-modifying therapy; therefore the best-fit category is neuropsychiatric symptom improvement rather than a disease-targeted biologic/small molecule or cognitive enhancer. If the intent were to classify by molecule type alone (small molecule analgesic), that could be noted, but the primary trial aim is behavioral symptom reduction, which determines the category."
    ],
    "agent_type": "T) Other",
    "explanation_agent": [
        "Reason: The intervention is scheduled acetaminophen (a symptomatic analgesic) given to treat pain with the stated intent of reducing agitation, mood disturbances, and other neuropsychiatric/behavioral symptoms in people with dementia \u2014 i.e., the trial aims to improve neuropsychiatric symptoms rather than to target Alzheimer\u2019s pathology or a specific molecular disease pathway. \ue200cite\ue202turn1search3\ue201",
        "Act: Extracted trial details \u2014 randomized, double\u2011blind, placebo\u2011controlled crossover testing acetaminophen 650 mg four times daily (qid) versus placebo in nursing\u2011home residents with dementia (registered NCT00012857). This identifies the drug as acetaminophen (paracetamol), a widely used small\u2011molecule analgesic. \ue200cite\ue202turn1search1\ue202turn1search3\ue201",
        "Act (mechanism): Acetaminophen\u2019s analgesic action is centrally mediated and incompletely understood (weak/central COX modulation, metabolism to AM404 affecting endocannabinoid and TRPV1/serotonergic pathways), i.e., it is not a disease\u2011modifying agent directed at canonical AD targets such as amyloid, tau, inflammation, synaptic receptors, etc. \ue200cite\ue202turn0search8\ue202turn0search3\ue201",
        "Act (evidence for symptom goal): Multiple studies/trials and reviews support that treating pain (including with acetaminophen/paracetamol) can reduce behavioral problems or improve mood/engagement in people with dementia, consistent with the trial\u2019s symptomatic neuropsychiatric focus. \ue200cite\ue202turn1search5\ue202turn1search6\ue202turn1search4\ue201",
        "Reflect: Mapping to the CADRO schema \u2014 the trial does not target a CADRO pathology category (A\u2013Q) such as amyloid, tau, inflammation, synaptic receptors, metabolism, vasculature, etc. Instead it addresses symptomatic/behavioral outcomes by treating pain with a general analgesic. Per the instruction to return T) Other when a trial does not fit CADRO therapeutic categories or is non\u2011disease\u2011targeted, the correct classification is 'T) Other'. No alternative CADRO category (e.g., R) Multi\u2011target) fits better because the intervention\u2019s mechanism is symptomatic analgesia rather than deliberate multi\u2011pathway disease modification. \ue200cite\ue202turn1search3\ue202turn0search8\ue201",
        "Web sources used (registry, mechanism, and outcome evidence): NCT00012857 trial registry / clinical trial summaries (trial details and acetaminophen 650 mg qid crossover). \ue200cite\ue202turn1search3\ue202turn1search1\ue201; Reviews of acetaminophen mechanisms (metabolism to AM404, central COX/serotonergic/endocannabinoid involvement). \ue200cite\ue202turn0search8\ue202turn0search3\ue201; Randomized trials and protocols assessing paracetamol/acetaminophen for behavior, QoL, or neuropsychiatric symptoms in dementia. \ue200cite\ue202turn1search5\ue202turn1search6\ue202turn1search4\ue201"
    ]
}